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A B S T R A C T
Objectives: Staphylococcus aureus is one of the most common pathogens causing nosocomial and
community-acquired infections associated with high morbidity and mortality. Mupirocin has been
increasingly used for treatment of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant
S. aureus (MRSA) infections. The aim of this study was to determine the prevalence of mupirocin-resistant
S. aureus (MuRSA), mupirocin-resistant MRSA (MuRMRSA), high-level MuRSA (HLMuRSA) and high-level
MuRMRSA (HLMuRMRSA) worldwide.
Methods: Online databases including Medline, Embase and Web of Science were searched (2000–2018) to
identify studies addressing the prevalence of MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA. STATA v.
software was used to interpret the data.
Results: Of the 2243 records identified from the databases, 30 and 63 studies fulfilled the eligibility
criteria for MuRSA and MuRMRSA, respectively. Finally, 27 and 60 studies were included separately for
HLMuRSA and HLMuRMRSA, respectively. The analyses revealed pooled and averaged prevalences of
MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA of 7.6% [95% confidence interval (CI) 6.2–9.0%], 13.8%
(95% CI 12.0–15.6%), 8.5% (95% CI 6.3–10.7%) and 8.1% (95% CI 6.8–9.4%), respectively.
Conclusion: Overall, these results show a global increase in the prevalence of HLMuRSA and HLMuRMRSA
among clinical S. aureus isolates over time. However, there was only a significant increase in the
prevalence of MuRMRSA compared with the other categories, especially MuRSA. Since mupirocin
remains the most effective antibiotic for MSSA and MRSA decolonisation both in patients and healthcare
personnel, a reduction of its effectiveness presents a risk for invasive infection. Monitoring of mupirocin
resistance development remains critical.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite the application of surveillance programmes in healthcare
settings, Staphylococcus aureus, a leading cause of nosocomial
infections, remains a major health problem worldwide, causing a
variety of infections [1–3]. Serious infections such as pneumonia
and bacteraemia and their sequelae result in prolonged hospital-
isation and a significant economic burden, especially in the case of
methicillin-resistant S. aureus (MRSA) [4–6]. Soon after the
introduction of penicillin into infectious diseases therapy in the
early 1940s, resistance to β-lactams started to develop in S. aureus.
After the first MRSA was identified in 1960, it was shown to harbour
the causal mecA gene encoding a modified penicillin-binding
protein (PBP), designated PBP2a, that has a lower affinity for
β-lactam antibiotics and confers methicillin resistance to staphylo-
cocci [7–9]. The onlyapproved antibiotic for decolonisation of MRSA
and methicillin-susceptible S. aureus (MSSA) both in patients and
healthcare personnel is mupirocin (pseudomonic acid A) [1]. This
antibiotic acts by binding to the enzyme leucine-specific tRNA
aminoacyl synthetase, thus inhibiting protein synthesis. Shortly
after widespread use of mupirocin for prolonged periods was
allowed, especially for decolonisation of healthcare personnel and
for bedsores and other skin lesions, resistance emerged [1]. Two
types of resistance to mupirocin have been described, with high-
level and low-level mupirocin resistance being associated with the
plasmid-mediated mupA gene and chromosomal point mutations,
respectively [1,10]. The high-level mupirocin resistance phenotype
can be transferred by conjugation between different staphylococcal
strains or species. The main mechanisms for development of high-
level mupirocin resistance are not completely clear, and even the
need for previous exposure to mupirocin to induce or select
emerging resistance is controversial in some studies [1,4]. The
emergence of mupirocin resistance in MRSA strains has been
described previously [11–13]. MRSA colonisation of the nose and
other body sites of patients, nurses and other healthcare personnel
defines the possible reservoirs of MRSAand plays a crucial role in the
induction and spread of staphylococcal infections [3,14,15]. Topical
use of mupirocin does not eliminate MRSA strains with high-level
mupirocin resistance and sometimes even low-level mupirocin
resistance [11]. Thereare currently no comprehensive data available
on the prevalence of mupirocin resistance in S. aureus isolates
around the world. Therefore, the aim of this study was to perform a
systematic review and meta-analysis of the scientific literature in
order to report the prevalence of mupirocin resistance among
S. aureus and MRSA isolates worldwide.
2. Methods
2.1. Literature search
A systematic search was performed for the prevalence of
mupirocin-resistant S. aureus (MuRSA), mupirocin-resistant MRSA
(MuRMRSA), high-level MuRSA (HLMuRSA) and high-level
MuRMRSA (HLMuRMRSA) based on the following keywords:(Staphylococcus aureus, Staphylococcus, mupirocin, Bactroban and
pseudomonic acid) using the three main electronic databases,
including Medline (via PubMed), Embase and Web of Science, from
2000 to 2018. The search was restricted to original articles
published in English that indicated the prevalence or incidence of
MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA. The bibliogra-
phies of identified articles were also searched for additional
articles mentioned among the literature references.
2.2. Inclusion and exclusion criteria
All original papers presenting cross-sectional studies on the
prevalence of MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA
were evaluated. The selected studies were analysed based on title,
abstract and full-text. Studies were included in the analysis based
on the following criteria: (i) original articles that provided
sufficient data on MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA;
and (ii) used standard methods, including (A) disk diffusion
method (B) agar dilution, microdilution and macrodilution
methods or Etest, and (C) molecular methods to detect MuRSA,
MuRMRSA, HLMuRSA and HLMuRMRSA according to Clinical and
Laboratory Standards institute (CLSI) 2018 guidelines (https://clsi.
org/standards/). Phenotypically, mupirocin resistance was deter-
mined based on (i) no zone of inhibition with a 200 mg mupirocin
disk or (ii) minimum inhibitory concentration (MIC) breakpoints
with susceptible being 4 mg/L, low-level mupirocin-resistant
being 8–256 mg/L and high-level mupirocin-resistant being 512
mg/L. Exclusion criteria were: (i) articles studying non-human
samples; (ii) studies considering (A) mupirocin-resistant bacteria
other than S. aureus and (B) other types of antibiotic resistance
except mupirocin; (iii) reviews; (iv) abstracts reported in confer-
ences; and (v) duplicate publications.
2.3. Data extraction and definitions
The author’s last name, date of the investigation, year of
publication, country/continent, number of S. aureus, MRSA,
MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA, the detection
method and source of isolates were extracted from the included
studies. The prevalence of MuRSA, MuRMRSA, HLMuRSA and
HLMuRMRSA isolates was also extracted. Two independent
researchers recorded the data to avoid bias.
2.4. Quality assessment
All reviewed studies were subjected to a quality assessment
(designed by the Joanna Briggs Institute) and only high-quality
investigations were evaluated in the final analysis.
2.5. Meta-analysis
The analysis was performed using Stata Statistical Software:
Release 14 (StataCorp LP, College Station, TX, USA). Data were
pooled using a fixed-effects model [16] and a random-effects
240 M. Dadashi et al. / Journal of Global Antimicrobial Resistance 20 (2020) 238–247model [17]. Statistical heterogeneity was assessed using the
Cochran Q and I2 statistical methods [18].
3. Results
3.1. Characteristics of included studies
After removing duplicates, 2243 articles were identified in the
database search. Based on title and abstract evaluation in a
secondary screening, 1043 and 850 of the chosen articles were
excluded, respectively (see Fig. 1, which also includes the reasons
for exclusion). In the next step, upon full-text review 30 and 63
articles were included (out of 350) for MuRSA and MuRMRSA,
respectively [4,10,11,19–84]. Finally, articles containing sufficient
data regarding HLMuRSA (27 studies) and HLMuRMRSASearch in electronic data ba
MEDLINE (vi a Pub Med): 84 
EMBASE: 108 6
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Fig. 1. Flow chart of study selection for inclusion in the systematic review. MuRSA, mup
resistant S. aureus; HLMuRSA, high-level MuRSA; HLMuRMRSA, high-level MuRMRSA.(60 studies) were included (Fig. 1). The characteristics of the
included articles are shown in Tables 1 and 2.
3.2. Prevalence of MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA
The pooled and averaged prevalences of MuRSA, MuRMRSA,
HLMuRSA and HLMuRMRSA were 7.6% [95% confidence interval
(CI) 6.2–9.0%] among 10 903 S. aureus isolates, 13.8% (95% CI 12.0–
15.6%) among 15 028 MRSA isolates, 8.5% (95% CI 6.3–10.7%) among
10 524 S. aureus isolates and 8.1% (95% CI 6.8–9.4%) among 14 834
MRSA isolates, respectively. Moreover, the pooled prevalence of
HLMuRSA among 753 MuRSA isolates and of HLMuRMRSA among
1582 isolates MuRMRSA was 60.1% (95% CI 47.1–74.4%) and 44.4%
(95% CI 31.8–57.0%), respectively (Tables 3 and 4).ses (n= 333 0)
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Kaur, 2014 [39] 2013–
2014






India 113 3 DDM, MIC Wound swabs, tissues
and pus




Rudresh, 2015 [69] 2014 India 98 25 DDM, MIC SSTI 25/98 (25.5) 8 8/98 (8.2) 8/25
(32.0)
Oommen, 2010 [61] 2008 India 98 1 DDM Pus, blood, catheters,
tracheal aspirates, urine
1/98 (1.0) 1 1/98 (1.0) 1/1 (100)
Gadepalli, 2007 [31] 2004–
2005




Hesami, 2014 [34] 2012–
2013










2013 Iran 39 5 DDM, MIC,
PCR










Nikfar, 2016 [58] 2015 Iran 53 2 DDM, PCR Nasal swabs 2/53 (3.8) NR NR NR
Yari, 2016 [81] 2015 Iran 150 7 DDM, PCR Skin 7/150 (4.7) 0 0/150
(0.0)
0/7 (0.0)
Saderi, 2008 [70] 2006–
2007











Arianpoor, 2015 [21] 2011–
2012




Yun, 2003 [82] 2000–
2002




Kwon, 2007 [42] 2006 Korea 108 9 MIC, PCR Clinical samples 9/108 (8.3) NR NR NR
Kwon, 2007 [42] 2003 Korea 218 5 MIC, PCR Clinical samples 5/218 (2.3) NR NR NR
Teo, 2011 [74] 2008–
2009
Singapore 18 7 MIC, PCR Clinical samples 7/18 (38.9) 7 7/18
(38.9)
7/7 (100)
Liu, 2009 [47] 2003–
2007
China 984 1 MIC Clinical samples 1/984 (0.1) 0 0/984
(0.0)
0/1 (0.0)
Liu, 2017 [46] 2010–
2011







2000 Russia 879 3 MIC Wound, abscess, blood,
peritoneal fluid
3/879 (0.3) 0 0/879
(0.0)
0/3 (0.0)








Turkey 77 35 DDM, PCR Blood, nostril, surgical
wound, urine, catheter








Rotger, 2005 [67] 1999–
2002
USA 50 4 MIC Clinical samples 4/50 (8.0) 1 1/50 (2.0) 1/4
(25.0)
Antonov, 2015 [19] 2012–
2013




Fritz, 2013 [29] 2007–
2009
USA 2425 50 DDM, MIC,
PCR








1346 42 MIC Blood, RTI, SSTI, UTI 42/1346 (3.1) 0 0/1346
(0.0)
0/42 (0.0)
Rubin, 2011 [68] 2006–
2008
















997 277 DDM, PCR,
VITEK1




DDM, disk diffusion method; MIC, minimum inhibitory concentration; SSTI, skin and soft-tissue infection; NR, not reported; RTI, respiratory tract infection; UTI, urinary tract
infection.
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different study periods
To determine longitudinal changes in the prevalence of
HLMuRSA and HLMuRMRSA in recent years, subgroups across
three periods of publication (before 2006, 2006–2010 and2011–2015) were designed (Tables 3 and 4). The incidence rate of
HLMuRSA and HLMuRMRSA strains gradually decreased from 4.7%
(95% CI 0.9–8.5%) of 5245 S. aureus isolates and 8.2% (95%
CI 5.6–10.8%) of 5888 MRSA isolates before 2006 to 3.3% (95% CI
1.1–5.4%) of 2958 isolates and 5.9% (95% CI 4.3–7.5%) of 7010
isolates in 2006–2010, reaching 11.2% (95% CI 5.0–17.4%) of 2321
S. aureus isolates and 14.3% (95% CI 10.6–18.0%) of 1936 MRSA
Table 2



















Liu, 2009 [47] 2003–2007 China 11 1 MIC Clinical samples 1/11 (9.1) NR NR NR
Liu, 2010 [11] 2005–2007 China 803 53 DDM, MIC Clinical samples 53/803 (6.6) 53 53/803 (6.6) 53/53 (100)
Liu, 2011 [48] 2008–2009 China 126 5 MIC Clinical samples 5/126 (4.0) 5 5/126 (4.0) 5/5 (100)
Kaur, 2014 [39] 2013–2014 India 20 2 DDM Nasal swabs 2/20 (10.0) 1 1/20 (5.0) 1/2 (50.0)
Kaur, 2015 [38] 2012–2014 India 36 19 DDM Pus, blood, sputum,
miscellaneous, urine
19/36 (52.8) 13 13/36 (36.1) 13/19 (68.4)
Jayakumar, 2013 [35] 2011–2012 India 46 1 DDM, MIC Wound swabs, tissue, pus 1/46 (2.2) 1 1/46 (2.2) 1/1 (100)
Rudresh, 2015 [69] 2014 India 22 5 DDM, MIC SSTI 5/22 (22.7) 1 1/22 (4.5) 1/5 (20.0)
Oommen, 2010 [61] 2008 India 48 1 DDM Pus, blood, catheters, tracheal
aspirates, urine
1/48 (2.1) 1 1/48 (2.1) 1/1 (100)
Krishnan, 2002 [41] 1994–1998 India 65 1 DDM, MIC, PCR Clinical samples 1/65 (1.5) 1 1/65 (1.5) 1/1 (100)
Gadepalli, 2007 [31] 2004–2005 India 110 10 DDM, MIC SSTI 10/110 (9.1) 9 9/110 (8.2) 9/10 (90.0)
Nicholson, 2010 [57] 2008 India 33 18 DDM BSI, SSTI, UTI, RTI 18/33 (54.5) 8 8/33 (24.2) 8/18 (44.4)
Mahmoodzadeh Hosseini, 2017
[50]
2011–2014 Iran 188 2 DDM, PCR Wounds, blood, pleural
effusion, bile
2/188 (1.1) 2 2/188 (1.1) 2/2 (100)
Hesami, 2014 [34] 2012–2013 Iran 50 5 DDM, MIC, PCR Blood, wounds, nares, urine,
sputum, catheter
5/50 (10.0) 5 5/50 (10.0) 5/5 (100)
Abbasi-Montazeri, 2013 [4] 2007–2008 Iran 78 11 DDM, PCR Nostrils 11/78 (14.1) 11 11/78 (14.1) 11/11 (100)
Shahsavan, 2012 [10] 2010–2011 Iran 62 42 DDM, PCR Burns patients 42/62 (67.7) 27 27/62 (43.5) 27/42 (64.3)
Watanabe, 2001 [80] 1990–1999 Japan 404 55 MIC Respiratory tract 55/404 (13.6) 0 0/404 (0.0) 0/55 (0.0)
Nakajima, 2011 [56] 2001–2009 Japan 178 6 MIC, PCR Blood or CSF 6/178 (3.4) 1 1/178 (0.6) 1/6 (16.7)
Fujimura, 2003 [30] 1997–2001 Japan 261 2 MIC Sputum, pharynx, pus, catheter 2/261 (0.8) 0 0/261 (0.0) 0/2 (0.0)
Fujimura, 2003 [30] 1998–2001 Japan 268 3 MIC Sputum, pharynx, pus, catheter 3/268 (1.1) 0 0/268 (0.0) 0/3 (0.0)
Fujimura, 2003 [30] 1999–2001 Japan 307 2 MIC Sputum, pharynx, pus, catheter 2/307 (0.7) 0 0/307 (0.0) 0/2 (0.0)
Fujimura, 2003 [30] 2000–2001 Japan 278 11 MIC Sputum, pharynx, pus, catheter 11/278 (4.0) 0 0/278 (0.0) 0/11 (0.0)
Fujimura, 2003 [30] 2001 Japan 254 6 MIC Sputum, pharynx, pus, catheter 6/254 (2.4) 0 0/254 (0.0) 0/6 (0.0)
Lee, 2013 [44] 2006–2009 Korea 456 62 MIC, PCR Clinical samples 62/456 (13.6) 9 9/456 (2.0) 9/62 (14.5)
Yun, 2003 [82] 2000–2002 Korea 237 15 MIC Clinical samples 15/237 (6.3) 15 15/237 (6.3) 15/15 (100)
Park, 2013 [62] 2011–2012 Korea 101 74 VITEK12, MIC Clinical samples 74/101 (73.3) 74 74/101
(73.3)
74/74 (100)
Park, 2012 [83] 2008–2009 Korea 193 27 MIC Clinical samples 27/193 (14.0) 11 11/193 (5.7) 11/27 (40.7)
Udo, 2001 [75] 1999 Kuwait 267 75 DDM, MIC Clinical samples 75/267 (28.1) 75 75/267
(28.1)
75/75 (100)
Udo, 2001 [75] 1999 Kuwait 72 55 MIC Clinical samples 55/72 (76.4) 19 19/72 (26.4) 19/55 (34.5)
Apisarnthanarak, 2011 [20] 2010 Thailand 9 2 MIC Nasal 2/9 (22.2) 0 0/9 (0.0) 0/2 (0.0)
Norazah, 2001 [60] 1997–1999 Malaysia 400 5 MIC Bloodstream, RTI, UTI,
abdominal cavity, tissue
infection, CSF, skin lesions,
catheters
5/400 (1.3) 4 4/400 (1.0) 4/5 (80.0)
Lim, 2010 [45] 2003–2007 Malaysia 188 10 DDM, MIC Clinical samples 10/188 (5.3) 0 0/188 (0.0) 0/10 (0.0)
Joshi, 2017 [37] 2014–2015 Nepal 29 15 MIC, PCR Nasal swabs 15/29 (51.7) 15 15/29 (51.7) 15/15 (100)
Nizamuddin, 2011 [59] 2008–2009 Pakistan 200 2 DDM Abscess, tracheal aspirates,
blood, urine
2/200 (1.0) 0 0/200 (0.0) 0/2 (0.0)
Teo, 2011 [74] 2008–2009 Singapore 11 6 MIC, PCR Clinical samples 6/11 (54.5) 6 6/11 (54.5) 6/6 (100)
Choudhury, 2012 [25] 2009–2010 Singapore 307 24 DDM Nasal 24/307 (7.8) 24 24/307 (7.8) 24/24 (100)
Europe
Us, 2009 [76] 2002–2004 Turkey 595 35 DDM, MIC Nosocomial infections 35/595 (5.9) 23 23/595 (3.9) 23/35 (65.7)
Sareyyüpoglu, 2008 [71] 2004–2005 Turkey 57 27 PCR, MIC Blood, nostril, surgical wound,
urine, catheter
27/57 (47.4) 27 27/57 (47.4) 27/27 (100)
Potel, 2007 [66] 1997–2005 Spain 210 9 DDM, MIC, PCR Clinical samples 9/210 (4.3) 3 3/210 (1.4) 3/9 (33.3)























Muñoz-Gallego, 2016 [55] 2012–2014 Spain 134 50 DDM, MIC, PCR Nasal swab, blood 50/134 (37.3) 37 37/134
(27.6)
37/50 (74.0)
González-Domínguez, 2015 [84] 2009–2010 Spain 118 30 DDM, MIC Clinical samples 30/118 (25.4) NR NR NR
González-Domínguez, 2016 [33] 2009–2010 Spain 147 40 DDM, MIC Clinical samples 40/147 (27.2) 40 40/147
(27.2)
40/40 (100)
Fang, 2016 [27] 2014 Sweden 743 5 MIC Clinical samples 5/743 (0.7) 3 3/743 (0.4) 3/5 (60.0)
Fawley, 2006 [28] 1999 UK 156 8 MIC Clinical samples 8/156 (5.1) 0 0/156 (0.0) 0/8 (0.0)
Mongkolrattanothai, 2008 [54] 2007–2008 UK 156 37 DDM, MIC Nasal swabs 37/156 (23.7) 8 8/156 (5.1) 8/37 (21.6)
Desroches, 2013 [26] 2011–2012 France 367 8 MIC Clinical samples 8/367 (2.2) 3 3/367 (0.8) 3/8 (37.5)
Kresken, 2004 [40] 2001 Germany 163 27 MIC Clinical samples 27/163 (16.6) 5 5/163 (3.1) 5/27(18.5)
Americas
Champion, 2014 [24] 2008–2010 USA 277 3 VITEK12, MIC Clinical samples from ICU
patients
3/277 (1.1) 0 0/277 (0.0) 0/3 (0.0)
Babu, 2009 [22] 2007–2008 USA 591 20 MIC Nasal swabs 20/591 (3.4) 3 3/591 (0.5) 3/20 (15.0)
Perkins, 2008 [65] 2006–2007 USA 409 247 MIC Sputum, pharyngeal cultures 247/409 (60.4) 5 5/409 (1.2) 5/247 (2.0)
Warren, 2016 [78] 2005–2012 USA 504 35 DDM, PCR Skin, wounds, trachea, sputum,
nasopharyngeal, lower
respiratory tract, blood, urine,
synovial fluid, catheter, body
fluids
35/504 (6.9) 35 35/504 (6.9) 35/35 (100)
Jones, 2007 [36] 2002–2004 USA 302 40 MIC, PCR Anterior nares 40/302 (13.2) 26 26/302 (8.6) 26/40
(65.0)
McDanel, 2013 [51] 2008–2011 USA 829 101 MIC, PCR Nasal swab 101/829 (12.2) 78 78/829 (9.4) 78/101
(77.2)
LaPlante, 2007 [43] 2004–2005 USA, America 98 9 MIC Nasal samples 9/98 (9.2) 5 5/98 (5.1) 5/9 (55.6)
McDougal, 2010 [52] 2005–2008 USA 823 22 PCR Blood, nares, tissue, sputum,
urine
22/823 (2.7) 22 22/823 (2.7) 22/22 (100)
Rotger, 2005 [67] 1999–2002 USA 15 4 MIC Clinical samples 4/15 (26.7) 1 1/15 (6.7) 1/4 (25.0)
Antonov, 2015 [19] 2012–2013 USA 65 36 MIC Clinical samples 36/65 (55.4) NR NR NR
Fritz, 2013 [29] 2007–2009 USA 755 14 DDM, MIC, PCR Skin (paediatrics) 14/755 (1.9) 14 14/755 (1.9) 14/14 (100)
Pérez-Roth, 2006 [64] 1998–2002 USA 375 48 DDM, MIC, PCR Wounds 48/375 (12.8) 48 48/375
(12.8)
48/48 (100)
Rubin, 2011 [68] 2006–2008 Canada 51 10 DDM, MIC Clinical samples 10/51 (19.6) 10 10/51 (19.6) 10/10 (100)
Vasquez, 2000 [77] 1990–1995 Tennessee,
USA
632 126 MIC Nares, sputum, wound, blood,
urine, percutaneous gastric
catheter
126/632 (19.9) 53 53/632 (8.4) 53/126
(42.1)
Pereira, 2014 [63] NR Brazil 11 0 DDM, MIC 0/11 (0.0) 0 0/11 (0.0) 0/0 (0.0)
Africa
Barakat, 2016 [23] 2013–2015 Egypt 73 13 MIC, PCR Pus, wound swabs 13/73 (17.8) 8 8/73 (11.0) 8/13 (61.5)
Shittu, 2006 [72] 2001–2003 South Africa 61 1 DDM, PCR Clinical samples 1/61 (1.6) 1 1/61 (1.6) 1/1 (100)
MIC, minimum inhibitory concentration; NR, not reported; DDM, disk diffusionmethod; SSTI, skin and soft-tissue infection; BSI, bloodstream infection; UTI, urinary tract infection; RTI, respiratory tract infection; CSF, cerebrospinal

























Pooled and averaged prevalences of mupirocin-resistant Staphylococcus aureus (MuRSA) and high-level MuRSA (HLMuRSA) based on study periods and continents.
Category Subcategory No. of studies No. of strains Prevalence (%) (95% CI)
MuRSA Overall MuRSA/S. aureus 30 769/10 903 7.6 (6.2–9.0)
Study period Before 2006 11 162/5463 3.0 (1.8–4.2)
2006–2010 7 96/3066 5.2 (2.5–7.8)
2011–2015 12 511/2374 15.2 (8.1–22.3)
Continent Asia 19 190/3282 7.3 (5.0–9.6)
Europe 4 80/2119 6.6 (2.4–10.8)
Americas 5 220/4278 10.5 (6.0–15.0)
Africa 2 279/1224 *
HLMuRSA Overall HLMuRSA/S. aureus 27 558/10 524 8.5 (6.3–10.7)
Study period Before 2006 9 71/5245 4.7 (0.9–8.5)
2006–2010 6 82/2958 3.3 (1.1–5.4)
2011–2015 12 405/2321 11.2 (5.0–17.4)
Continent Asia 16 121/2903 6.4 (3.9–8.9)
Europe 4 42/2119 1.0 (0.4–1.7)
Americas 5 159/4278 10.6 (0.0–21.2)
Africa 2 236/1224 *
Overall HLMuRSA/MuRSA 27 558/753 60.1 (47.1–74.4)
Study period Before 2006 10 71/157 42.3 (30.5–54.1)
2006–2010 6 82/87 16.7 (13.2–46.5)
2011–2015 11 405/509 72.0 (60.6–83.3)
Continent Asia 16 121/174 61.2 (43.6–78.7)
Europe 4 42/80 23.3 (8.2–38.5)
Americas 5 159/220 59.1 (37.9–77.6)
Africa 2 236/279 *
CI, confidence interval.
* Cannot be analysed using meta-analysis methods.
Table 4
Pooled and averaged prevalences of mupirocin-resistant methicillin-resistant Staphylococcus aureus (MuRMRSA) and high-level MuRMRSA (HLMuRMRSA) based on study
periods and continents.
Category Subcategory No. of studies No. of strains Prevalence (%) (95% CI)
MuRMRSA Overall MuRMRSA/MRSA 63 1649/15 028 13.8 (12.0–15.6)
Study period Before 2006 25 590/5899 10.5 (8.0–13.0)
2006–2010 23 781/7128 13.4 (10.1–16.6)
2011–2015 15 278/2001 23.8 (18.5–29.0)
Continent Asia 35 633/6118 13.4 (10.9–15.9)
Europe 12 287/3050 14.1 (10.3–18.0)
Americas 14 715/5726 15.1 (10.6–19.6)
Africa 2 14/134 *
HLMuRMRSA Overall HLMuRMRSA/MRSA 60 860/14 834 8.1 (6.8–9.4)
Study period Before 2006 24 315/5888 8.2 (5.6–10.8)
2006–2010 22 354/7010 5.9 (4.3–7.5)
2011–2015 14 191/1936 14.3 (10.6–18.0)
Continent Asia 34 391/6107 12.1 (9.2–14.9)
Europe 11 160/2932 8.0 (5.4–10.6)
Americas 13 300/5661 5.9 (3.8–7.9)
Africa 2 9/134 *
Overall HLMuRMRSA/MuRMRSA 60 860/1582 44.4 (31.8–57.0)
Study period Before 2006 24 315/589 48.4 (34.7–62.1)
2006–2010 22 354/751 30.6 (5.2–55.9)
2011–2015 14 191/242 60.8 (49.7–71.9)
Continent Asia 34 391/632 47.4 (30.3–64.6)
Europe 11 160/257 44.1 (22.9–65.4)
Americas 13 300/679 35.6 (12.3–58.9)
Africa 2 9/14 *
CI, confidence interval.
* Cannot be analysed using meta-analysis methods.
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MuRSA and MuRMRSA prevalence as well as the changes in
HLMuRSA and HLMuRMRSA prevalence in all three periods are
shown in Tables 3 and 4.
3.4. Prevalence of MuRSA, MuRMRSA, HLMuRSA and HLMuRMRSA in
different regions of the world
Tables 3 and 4 also show the prevalences of MuRSA, MuRMRSA,
HLMuRSA and HLMuRMRSA based on geographic area in the
subgroup analysis of the included studies. The frequency ofHLMuRMRSA in Asia was 1.5- and 2.1-fold higher than the
frequency in Europe and the Americas, respectively. Tables 5 and 6
show the prevalence of MuRSA, MuRMRSA, HLMuRSA and
HLMuRMRSA in different countries.
4. Discussion
The rate of mupirocin resistance among clinical S. aureus
isolates varies according to geographic region and/or patient
population. According to this systematic review, resistance to
mupirocin accounted for 7.6% (95% CI 6.2–9.0%) of clinical S. aureus
Table 5
Pooled and averaged prevalences of mupirocin-resistant Staphylococcus aureus (MuRSA) and high-level MuRSA (HLMuRSA) based on countries.
Category Subcategory No. of studies No. of strains Prevalence (%) (95% CI)
MuRSA Overall MuRSA/S. aureus 30 769/10 903 7.6 (6.2–9.0)
Country India 5 43/547 6.6 (1.8–11.5)
Iran 8 103/1054 9.9 (5.1–14.6)
Korea 3 30/645 4.5 (1.6–7.4)
USA 3 166/2833 13.8 (0.1–33.7)
HLMuRSA Overall HLMuRSA/S. aureus 27 558/10 524 8.5 (6.3–10.7)
Country India 5 22/547 3.1 (0.9–5.3)
Iran 7 71/1054 9.1 (3.4–14.8)
USA 3 147/2833 10.1 (0.2–23.1)
Overall HLMuRSA/MuRSA 27 558/753 60.1 (47.1–74.4)
Country India 5 22/43 58.0 (24.3–91.7)
Iran 7 71/103 58.4 (31.5–85.4)
USA 3 147/166 59.1 (32.6–87.3)
CI, confidence interval.
Table 6
Pooled and averaged prevalences of mupirocin-resistant Methicillin-resistant Staphylococcus (MuRMRSA) and high-level MuRMRSA (HLMuRMRSA) based on countries.
Category Subcategory No. of studies No. of strains Prevalence (%) (95% CI)
MuRMRSA Overall MuRMRSA/MRSA 63 1649/15 028 13.8 (12.0–15.6)
Country China 3 56/940 6.1 (4.6–7.6)
India 8 57/380 15.2 (7.6–22.8)
Iran 4 60/378 22.6 (0.9–44.3)
Japan 7 85/1950 3.2 (1.3–5.1)
Korea 4 178/987 26.2 (8.9–43.5)
Spain 5 140/813 17.4 (6.1–28.6)
USA 12 579/5043 15.1 (10.2–20)
HLMuRMRSA Overall HLMuRMRSA/MRSA 60 860/14 834 8.1 (6.8–9.4)
Country India 8 35/380 6.8 (2.4–11.3)
Iran 4 45/378 16.2 (1.8–30.7)
Japan 7 1/1950 0.6 (0.0–1.7)
Korea 4 100/987 20.7 (6.9–34.6)
Spain 4 94/813 14.7 (4.6–24.8)
USA 12 237/5043 5.1 (3.1–7.2)
Overall HLMuRMRSA/MuRMRSA 60 860/1582 44.4 (31.8–57.0)
Country India 8 35/57 57.6 (32.8–82.6)
Iran 4 45/60 64.3 (49.8–78.8)
Japan 7 1/85 16.7 (0.1–46.5)
Korea 4 100/178 26.3 (0.7–51.9)
Spain 5 94/140 56.2 (16.7–95.8)
USA 12 237/579 59.1 (35.7–90.7)
CI, confidence interval.
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strains. Worryingly, the prevalence of MuRSA strains in certain
regions and institutes will be higher than the prevalence of 7.6%
found here. The Americas (10.5%) showed the highest pooled
prevalence of MuRSA strains, whilst in Europe and Asia this figure
was found to be 6.6% and 7.3%, respectively. An increasing trend in
the overall prevalence of MuRSA strains in the period 2011–2015
was also observed. One potential explanation for this is a
significant increasing trend among overall S. aureus infections
and a shift in antibiotic pressures. Although mupirocin as a
cornerstone of decolonisation regimens is widely used for
eradication of S. aureus nasal colonisation and the control of
MRSA transmission in healthcare settings, the emergence of
mupirocin resistance among S. aureus isolates will result in a
decrease in the efficacy of this antibiotic [39,84,85]. Physicians
should be continuously educated about the problem of unrestrict-
ed and widespread use of mupirocin in patients with S. aureus
infections and also in individuals not carrying S. aureus as it may
lead to cross-transferable resistance in coagulase-negative staph-
ylococci. The current systematic review showed that the preva-
lence of resistance to mupirocin among MRSA strains was 13.8%
(95% CI 12.0–15.6%) compared with 7.6% for MSSA. Although
mupirocin effectively reduces MRSA carriage [78], colonisation andcross-transmission of MRSA in community and healthcare settings
as well as the high relative prevalence of MuRMRSA strains again
highlights the need for physician’s awareness. Moreover, control
measures as a powerful framework and strategy for reducing the
prevalence of MuRMRSA strains should also be taken into
consideration. The current analyses showed that the prevalence
of high-level mupirocin resistance among S. aureus (8.5%, 95% CI
6.3–10.7%) was almost the same as for MRSA (8.1%, 95% CI 6.8–
9.4%). This finding highlights that both S. aureus and MRSA isolates
must be evaluated routinely in terms of resistance to mupirocin.
According to this analysis, the rate of HLMuRMRSA in Asia (12.1%)
was found to be higher than the reported rate in Europe (8.0%) and
the Americas (5.9%). Therefore, it is reasonable to assume that
overuse or inappropriate, less controlled use of mupirocin would
similarly be higher in Asian countries, which may be linked to easy
access to antibiotics without prescription, inexpensive drugs, a
high rate of antibiotic misuse and the frequency of empirical
treatment in these regions. Furthermore, because of differences in
the number of studies and studied isolates, the rates of resistance
in different countries are not reliable. Overall, the prevalence of
resistance to mupirocin among S. aureus and MRSA isolates in the
years 2011–2015 was higher than other study periods. Further-
more, it is notable that today both laboratory personnel and
246 M. Dadashi et al. / Journal of Global Antimicrobial Resistance 20 (2020) 238–247clinicians need to be educated to develop diagnostic tests and in
test interpretation. Regarding routine diagnosis of mupirocin
resistance, it seems not to be performed everywhere [36]. The
present study has limitations that should be considered when
interpreting the findings. First, analysis of two African studies was
not possible using meta-analysis because meta-analysis software
such as STATA and comprehensive meta-analysis cannot analyse
data from less than three studies. Second, only published scientific
studies were considered for the present meta-analysis and
potential publication bias had to be considered. Third, we could
not fully represent the prevalence of MuRSA and MuRMRSA since
there were insufficient data regarding this topic.
5. Conclusion
In summary, this systematic review demonstrated the highly
significant prevalence of mupirocin resistance among clinical S.
aureus and MRSA isolates. The findings support the notion that
routine diagnostic testing, identification of carriers, national and
organisational guidelines for infection control, surveillance and
antibiotic stewardship measures, education and mupirocin pro-
phylaxis are extremely important in the successful reduction of
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